Patent-family-84943760

Patent Number: WO-2024133648-A2

Publication Year: 2024

Application Year: 2023

Priority Year: 2022

Jurisdictions: WO

Status: N/A

Inventors:

GALLER GUNTHER ROLAND DR RAHMAN SHAMIM HERBERT

Applicants:

  1. Novo Nordisk (Denmark)
    2. [NORA names: Novo Nordisk; Private Research; Denmark; Europe, EU; Nordic; OECD]

Abstract

The technical field of the present invention is cell therapy, more particularly cell replacement therapy. The invention relates to a cell comprising on its cell surface no fully functional form of at least one protein selected from the list consisting of ULBP-2, CD112, CD155, B7-H3, ULBP-3, ULBP-4, ULBP-5, ULBP-6, B7-H6, B7-H7, MICA, MICB, CD48, CD58, CD70, CD1d, CD318, TRAIL-R1 and TRAIL-R2. The invention also relates to cell compositions and uses thereof.

Patent Family Records (1)

NK CELL ACTIVATING RECEPTOR LIGAND KNOCKOUTS FOR USE IN CELL THERAPY

NOVO NORDISK AS, Novo Nordisk (Denmark) GALLER GUNTHER ROLAND DR, RAHMAN SHAMIM HERBERT

2024, WO-2024133648-A2

Data Provider: Digital Science

LINKS
+

External Systems

SUBJECTS
+

PATENT CATEGORIES
+

METRICS
+

Citation Metrics

Times Cited in Patents: 0external link

References to Patents: [No Data Available]

References to Publications: 0external link